BIOLOGICAL SAMPLE HOLDER AND HANDLER
20210252518 · 2021-08-19
Inventors
- Triantafyllos P. Tafas (Rocky Hill, CT, US)
- Seth Winfree (Plainfield, IN, US)
- Scott W. Reed (Winchester, CT, US)
Cpc classification
B01L2200/10
PERFORMING OPERATIONS; TRANSPORTING
G01N2015/1445
PHYSICS
B01L3/0203
PERFORMING OPERATIONS; TRANSPORTING
G01N21/0303
PHYSICS
B01L3/502715
PERFORMING OPERATIONS; TRANSPORTING
B01L9/065
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/02
PERFORMING OPERATIONS; TRANSPORTING
B01L3/50
PERFORMING OPERATIONS; TRANSPORTING
International classification
Abstract
The present invention provides a biological sample holder and handler system for cell-based liquid biopsies. The system is useful for performing diagnostic assays, based on a simple blood sample. For example, the system is useful for delivering precision cancer diagnoses that improve patient outcomes by optimizing treatment options, monitoring therapy efficacy, characterizing metastasis and assessing treatment toxicity
Claims
1-37. (canceled)
38. A device comprising: (a) a chamber configured to receive a container, wherein the container holds a biological sample, and wherein the chamber comprises: (i) a first end configured to receive at least a portion of the container; (ii) a second end; and (iii) an interior wall connecting the first end and the second end, wherein the interior wall comprises: (1) a first portion disposed between the first end and the second end, wherein the first portion is configured to permit directing of a light towards the biological sample when the biological sample is disposed within the chamber; and (2) a second portion disposed between the first end and the second end, wherein the second portion is configured to permit detection, by a detector, of the biological sample when the biological sample is exposed to the light; (b) an optical source coupled to the chamber and positioned at the first portion of the interior wall, wherein the optical source is configured to direct the light through the first portion and towards the biological sample; and (c) the detector, wherein the detector is coupled to the chamber and positioned at the second portion of the interior wall, and wherein the detector is configured to detect the biological sample through the second portion upon the exposure to the light.
39. The device of claim 38, wherein the first portion of the interior wall has a first optical axis, wherein the second portion of the interior wall has a second optical axis, and wherein, if the biological sample is extruded out of the container while the biological sample is within the chamber, then the chamber holds the extruded biological sample at an intersection of the first optical axis of the first portion and the second optical axis of the second portion.
40. The device of claim 39, wherein the first optical axis of the first portion and the second optical axis of the second portion are substantially perpendicular to each other.
41. The device of claim 38, wherein the first portion of the interior wall and the second portion of the interior wall are disposed at a substantially same distance between the first end and the second end of the chamber.
42. The device of claim 41, wherein the chamber further comprises a third portion, wherein the third portion is disposed at the substantially same distance between the first end and the second end of the chamber, and wherein the third portion is configured to provide access via an instrument to a portion of the biological sample.
43. The device of claim 38, wherein the chamber further comprises an optical lens coupled to the first portion of the interior wall, wherein the optical lens is configured to orient the light from the optical source and towards the biological sample.
44. The device of claim 38, wherein the chamber further comprises an optical lens coupled to the second portion of the interior wall, wherein, if an additional light is emitted from the biological sample when the biological sample is exposed to the light, then the optical lens is configured to orient the additional light from the biological sample and towards the detector.
45. The device of claim 38, wherein the light is a laser light.
46. The device of claim 38, wherein the light is a light sheet.
47. The device of claim 38, wherein the detector is for selective plane illumination microscopy.
48. The device of claim 38, wherein the detector is a microscope.
49. The device of claim 38, wherein the chamber is configured to hold a liquid.
50. The device of claim 38, wherein the container is a capillary tube.
51. A system comprising: a container configured to hold a biological sample; and a device operatively coupled to the container, wherein the device comprises: (a) a chamber configured to receive the container when the container is holding the biological sample, wherein the chamber comprises: (i) a first end configured to receive at least a portion of the container; (ii) a second end; and (iii) an interior wall connecting the first end and the second end, wherein the interior wall comprises: (1) a first portion disposed between the first end and the second end, wherein the first portion is configured to permit directing of a light towards the biological sample, wherein the biological sample is disposed within the chamber; and (2) a second portion disposed between the first end and the second end, wherein the second portion is configured to permit detection, by a detector, of the biological sample when the biological sample is exposed to the light; (b) an optical source coupled to the chamber and positioned at the first portion of the interior wall, wherein the optical source is configured to direct the light through the first portion and towards the biological sample; and (c) the detector, wherein the detector is coupled to the chamber and positioned at the second portion of the interior wall, and wherein the detector is configured to detect the biological sample through the second portion upon exposure to the light.
52. The system of claim 51, wherein the container has an inner diameter between about 0.5 millimeters and about 10 millimeters.
53. The system of claim 51, further comprising a moving unit configured to direct a relative movement between the container and the device, wherein the relative movement comprises insertion of the at least the portion of the container, through the first end of the chamber, and into a space within the interior wall of the chamber.
54. The system of claim 52, wherein the first portion of the interior wall has a first optical axis, wherein the second portion of the interior wall has a second optical axis, and wherein the moving unit is further configured to extrude the biological sample out of the at least the portion of the container while the biological sample is within the space, such that the chamber holds the extruded biological sample at an intersection of the first optical axis of the first portion and the second optical axis of the second portion.
55. The system of claim 54, wherein the first optical axis of the first portion and the second optical axis of the second portion are substantially perpendicular to each other.
56. The system of claim 51, wherein the first portion of the interior wall and the second portion of the interior wall are disposed at a substantially same distance between the first end and the second end of the chamber.
57. The system of claim 56, wherein the chamber further comprises a third portion, wherein the third portion is disposed at the substantially same distance between the first end and the second end of the chamber, and wherein the third portion is configured to provide access via a tube to at least a portion of the biological sample.
Description
BRIEF DESCRIPTIONS OF THE DRAWINGS
[0079] The skilled artisan will understand that the drawings primarily are for illustrative purposes and are not intended to limit the scope of the inventive subject matter described herein. The drawings are not necessarily to scale; in some instances, various aspects of the inventive subject matter disclosed herein may be shown exaggerated or enlarged in the drawings to facilitate an understanding of different features. In the drawings, like reference characters generally refer to like features (e.g., functionally similar and/or structurally similar elements).
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
DETAILED DESCRIPTION OF THE INVENTION
[0088] The biological sample holder and handler system of the present invention comprises several components and utilizes advanced characterization and quantitation techniques to provide high resolution, accuracy, and sensitivity.
Selective Plane Illumination Microscopy (SPIM)
[0089] Fluorescence light sheet microscopy (FLSM) is a fluorescence microscopy technique in which a sample is illuminated by a laser light sheet (i.e. a laser beam which is focused in only one direction) perpendicularly (i.e. orthogonally or 90 degrees to the direction of observation. The light sheet can be created using e.g. cylindrical lens or by a circular beam scanned in one direction to create the light sheet. As has been reported, only the actually observed section of a sample is illuminated. Therefore, this method is reported to reduce the photodamage and stress induced on a living sample. Also, it has been reported that the good optical sectioning capability reduces the background signal and thus creates images with higher contrast, comparable to confocal microscopy. Furthermore, selective plane illumination microscopy (SPIM) and fluorescence microscopy techniques in which a focused sheet of light serves to illuminate the sample have become increasingly popular in developmental studies. Fluorescence light-sheet microscopy bridges the gap in image quality between epifluorescence microscopy and high-resolution imaging of fixed tissue sections. In addition, high depth penetration, low bleaching and high acquisition speeds make light-sheet microscopy ideally suited for extended time-lapse experiments. See, Huisken et al (2009). Selective plane illumination microscopy techniques in developmental biology. Development 136, 1963-1975 doi:10.1242/dev.022426. FLSM systems can be purchased from various companies such as Zeiss, Leica, or Olympus. These systems can also be built for research purposes following designs offered through open source groups such as OpenSPIM or SPIM-fluid.
[0090] See, http://openspim.org/Welcome_to_the_OpenSPIM_Wiki; and https://doi.org/10.1364/BOE.6.004447.
Systems and Methods of the Present Invention
[0091] The system and method of the present invention can accurately detect epithelial, mesenchymal, or stemness-like CTCs, including intermediate phenotypes, because it is designed to quantitatively detect multiple CTC biomarkers. It provides fully automated CTC detection in patient blood samples for clinical diagnosis, academic research and drug development. The present system does not require enrichment because its high-resolution and high-speed microscope can scan and analyze every nucleated cell from the patient sample and deliver very sensitive detection of CTCs or other blood cell subpopulations such as T-cells.
[0092] The system has the unique ability to observe live cell preparations in addition to detecting and characterizing CTCs without enrichment. The system enables (i) spatial and temporal characterization of disease progression, and (ii) real-time observation of live CTC phenotypes by ex vivo imaging.
[0093] The system of the present invention can include an aqueous solution filled cell observation chamber. This enables observation of either fixed or live cell preparation. The chamber can be equipped with a media recirculation system which enables perfusion of the cells with solutions that can contain: (i) biomarkers such as antibodies or fluorescence in situ hybridization (FISH) probes appropriately labeled for enumeration and quantitation, (ii) substances for staining DNA or other molecules, (iii) agents including therapeutic substances, viral suspensions etc. that can affect the physiology of targeted live cells, (iv) de-staining solutions, and (v) cleaning and de-contamination solutions.
[0094] The system's “lossless” CTC detection is applicable to different cancer types. By scanning every nucleated cell from the blood sample and utilizing multiple markers associated with different CTC phenotypes. The system enables detection of epithelial, mesenchymal and stemness-like CTCs. Quantitative imaging of biomarker levels also allows detection of CTCs transitioning between different CTC phenotypes.
[0095] Unlike other microscopic methods, the system's high-resolution microscopy has very low phototoxicity (i.e. the light-induced degradation of photosensitive components or in general adverse light-induced effects), which permits multiple imaging sessions of a given specimen, in successive time points.
[0096] The system of the present invention includes a cell aspiration device that allows removal of target cells from the specimen (including while live), for further molecular, single-cell testing. CTCs isolated by the system can be used as a tissue source for drug sensitivity testing by utilizing subsequent ex vivo cultures and for the detection of specific mutations in CTC-derived cell lines. In CTC-derived cell lines, cells can be studied for their resistance to specific chemotherapy or targeted therapies or combinations of the above. Drug sensitivity testing can be carried out also in mouse xenograft models. The clinical utility of the CTC models can depend on (i) the percentage of patients in which CTC will be detected and (ii) whether the CTC models can reliably capture response to different drugs. The system and methods of the present invention can aid in combining CTC genomic and transcriptomic analyses together with drug sensitivity testing in CTC-derived cell lines and mouse models; this can provide new insights for driving personalized cancer treatment.
Biological Sample Holder and Handler
[0097] The holder and handler of the present invention is a system that allows ex vivo observation of cells that have been stained with vital stains for CTC-specific biomarkers and maintained alive for periods of time supported by a 3-dimensional culture subsystem. A specially designed cell chamber will be fitted for input and output of culture media, gas regulation and control of environmental variables (temperature, pH etc). This will allow ex vivo observation of cells while perfused with culture media which may contain various substances. The chamber will be fitted with a micromanipulator (handler) used to isolate target cells under direct observation. Both the chamber and the micromanipulator can be operated automatically by a system computer and software system.
[0098] The ex vivo liquid biopsy will offer longitudinal observation of target cells, e.g. CTCs and WBCs and assessment of desired and undesired toxicity of therapeutic drug cocktails before used for patient treatment. This will drive precision medicine for improved outcomes and reduced adverse effects to the patient. Cell isolation will enable CTC genomic and transcriptomic analysis that may reveal improved therapeutic options, tuned to the patient's current disease status.
[0099] The sample holder and handler of the present invention, combined with deep quantitation of every cell the specimen, have the potential to become an important precision medicine tool. Deep CTC characterization and single-cell, genomic/transcriptomic analysis will enable the oncologist to select a treatment that is synchronized with the current disease stage. Ex vivo assessment of how a selected drug or drug combination affects CTCs and WBCs in the patient's blood will have to be studied against patient outcomes. However, it has the potential to revolutionize therapy selection and longitudinally, help in turning cancer from a devastating to a chronic disease.
[0100] A central computer system (not shown) operates a software package that (a) acquires and processes images of the biological specimen's features for identification and quantitation, (b) actuates the motorized components, pumps, sensors of the system, (c) operates a robotic arm that loads and unloads samples, and (d) handles digital information managed in local or wide area networks. The central computer system may utilize local or distributed processing protocols.
[0101] The system also includes or is coupled to a tunable laser source or multiple single wavelength laser sources, complete with light management optical path(s). An optical system modulating the light sheet can combine bilateral illumination to produce the sheet illumination for SPIM.
[0102] Imaging is done by illuminating the specimen with narrow spectrum excitation light provided by monochromatic and/or tunable laser sources. Images of the resulting emission are acquired by high sensitivity monochrome cameras on a field by field basis. These images are combined in 3-dimensional stacks, which are then analyzed for quantitative measurement of biomarker levels in the individual cells.
[0103] In operation, a biological specimen that can include live cells is stained with a variety of markers against proteins, nucleic acids or other cellular components and encased in an appropriately shaped cylindrical sheath to be fitted on a biological sample holder. The preparation is made by mixing the cell suspension with agarose or other hydrogels compatible with preserving the subcellular structure of the embedded cells, at a temperature where the solution is still liquid. In addition to the cells, fluorescent beads that serve the role of fiducial reference for the identified cells are added to the solution. The liquid cell/bead/gel suspension is aspirated in tubing that is chosen to be transparent to the fluorescence light regime utilized. After being allowed to solidify, the specimen can be visualized in the light path. The biological specimen is mounted on a specimen holder loaded onto the microscope stage.
[0104] All combinations of the foregoing concepts and additional concepts discussed in greater detail below (provided such concepts are not mutually inconsistent) are part of the inventive subject matter disclosed herein. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are part of the inventive subject matter disclosed herein. The terminology used herein that also may appear in any disclosure incorporated by reference should be accorded a meaning most consistent with the particular concepts disclosed herein.
[0105]
[0106]
[0107]
[0108]
[0109] A micropipette 9 for extracting cells or particles of interest and an access port for the micropipette 9A on the fluid chamber 5 is shown. It is important that the micropipette can access the sample at the intersection of the optical axes of the light paths from the illumination and detection lenses.
[0110]
[0111]
[0112]
[0113]
[0114] In the foregoing embodiments, it should be noted that the illumination lens 9A and the detection lens 9B, as well as the illumination and detection means, can be swapped around, so long as their orientation is orthogonal. Also, the openings 11A and 11B of the lens holder and the openings 14A and 14B of the sample chamber would also be concurrently swapped in such a situation.
Methods and Use of the Holder and Handler
[0115] A cell suspension can be observed in SPIM instrument mounted in fixture and embedded in hydrogels that allow cell perfusion with fluorescently labeled antibodies, fluorescence in situ hybridization FISH probes, and other stains as well as media that can sustain ex vivo cell observation.
Selection of Embedding Gel and Specimen Fixture for SPIM Cell Suspensions
[0116] The following steps are performed: Compare performance of embedding gels including agarose, collagen, polyacrylamide and tubing such as micro-perforated, fluorinated polyethylene (FPE) and glass both for fixed and live cells. Optimize fixation/permeabilization protocols. Assess need of antifading for fluorescence bleaching. Adapt SPIM image acquisition to materials chosen. Quantitative analysis of cell staining and morphology changes via 3d image analysis with QCDx imaging software.
Viability of Live Cell Preparations in Longitudinal Imaging Sessions.
[0117] Explore prototype chamber design fitted with computer-controlled, microfluidic media circulation, gas exchange mechanism and environmental sensors. Evaluate vital fluorescence stains for immunostaining and nuclear counterstaining and viability stains. Quantitative morphological changes in target cells to establish acceptable longitudinal ex vivo imaging periods. The holder and handler has design requirements for the chamber, specimen fixture, tube and embedding gel that will enable longitudinal imaging of cell suspensions, fixed or ex vivo.
Application
[0118] The present invention can comprise instruments and kits for the detection and characterization of CTCs and other target cell populations
References:
[0119] The following references have been cited above corresponding to the following numbering.
[0120] 1. Hayes et al., Clin Cancer Res. 2006; 12(14): 4218-4224.
[0121] 2. Cohen et al., J Clin Oncol. 2008; 26(19):3213-3221.
[0122] 3. de Bono et al., Clin Cancer Res 2008; 14:6302-6309
[0123] 4. Bidard et al., Lancet Oncol. 2014; 15:406-14.
[0124] 5. Zhaomei et al., Int. J. Mol. Sci. 2016; 17,1665; doi:10.3390/ijms17101665
[0125] 6. Peeters et al., Br. J. Cancer 2013; 108: 1358-1367.
[0126] 7. Joosse et al., EMBO Mol Med 2015; 7: 1-11.
[0127] 8. Alix-Panabieres et al., Nature Reviews Cancer 2014; 14: 623-631.
[0128] 9. Ferrarini et al. PLOS ONE 2018; doi:10.1371/journal.pone.0193689
[0129] 10. Scher et al., JAMA Oncol. 2016; doi:10.1001/jamaonco1.2016.1828
[0130] 11. Dittamore et al., J Clin Oncol. 2018; 36, (suppl; abstr 5012).
[0131] 12. Franken et al., Breast Cancer Research 2012; 14:R133.
[0132] 13. Zhang et al. BMC Cancer 2016; 16:526; doi:10.1186/s12885-016-2578-5
[0133] 14. Huisken et al. Development 2009; 136, 1963-1975; doi:10.1242/dev.022426
[0134] While various inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.
[0135] Also, various inventive concepts may be embodied as one or more methods, of which an example has been provided. The acts performed as part of the method may be ordered in any suitable way. Accordingly, embodiments may be constructed in which acts are performed in an order different than illustrated, which may include performing some acts simultaneously, even though shown as sequential acts in illustrative embodiments.
[0136] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.
[0137] The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”
[0138] The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
[0139] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity’ such as “either”’ “one of” “only one of” or “exactly one of” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
[0140] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc. In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
Equivalents
[0141] In the specification, the singular forms also include the plural forms, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the case of conflict, the present specification will control.
Incorporation by Reference
[0142] The entire disclosure of each of the patent documents, including certificates of correction, patent application documents, scientific articles, governmental reports, web sites, and other references referred to herein is incorporated by reference herein in its entirety for all purposes. In case of a conflict in terminology, the present specification controls.